Global #1 Gene Synthesis Provider, But The Stock Is Fairly Valued
Valuation of Genscript Biotech (1548 HK) reached ~$9 billion in Hong Kong. We do believe the stock has ~11% limited upside potential with free cash...
407 Views
China Healthcare Weekly (Aug.27)
This article analyzed the logic of China's healthcare sector while its economy is being restructured, two strategies to deal with centralized...
323 Views
Yidu Tech IPO Valuation: Attractive at the Low-End but Superior Growth Profile Justifies the Premium
The big data and AI solutions provider for healthcare sector in China, Yidu Tech has set the terms for its IPO and in this insight, we examine Yidu...
732 Views
Legend Biotech IPO: Pass on Valuation
Legend Biotech (LEGN US)Â is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...
519 Views
COVID-19 and ESG: Tencent, Alibaba Lead in Coronavirus Aid for Asia Pacific Region
"Social" has been a third-wheel ESG pillar for a long time. Not that it matters any less, and there is plenty of evidence that strong Social-pillar...
783 Views